Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023 Pharmaceutical Investing
The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation to Expand with Amgen's Commitment of $8 Million Pharmaceutical Investing
BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT Combination in Advanced Metastatic Breast Cancer Technology Investing
JUVÉDERM® VOLUX XC FOR IMPROVEMENT OF JAWLINE DEFINITION NOW AVAILABLE NATIONWIDE Pharmaceutical Investing
Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx for the Treatment of Recurrent Pericarditis Pharmaceutical Investing
BriaCell Announces New Patent Issuance, Bria-OTS IND Timing Guidance, and Additional Clinical Sites to Boost Enrolment Pharmaceutical Investing
AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets Pharmaceutical Investing
